Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Nutrien Ltd (NTR) Price & Performance

Charles River Laboratories Intl. IncTrade
Nutrien LtdTrade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Nutrien Ltd — how do they compare? Charles River Laboratories Intl. Inc trades at $288.87 (market cap $13.46B), while Nutrien Ltd trades at $66.6 (market cap $32.05B). The key difference: Nutrien Ltd is far larger — about 2.4× Charles River Laboratories Intl. Inc's market cap, and Nutrien Ltd pays a 3.27% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.

CRLNTR
Market Cap
$13.46B$32.05B
Sector
HealthBasic Materials
52-Week High
$282.00$83.94
52-Week Low
$145.57$53.64
Enterprise Value
$16.30B$43.86B
Dividend Yield
3.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $284.37, up 2.66% today and near its 52-week high, reflecting strong bullish momentum. The stock has consistently beaten earnings estimates in recent quarters, including a Q2 2026 EPS of $3.02 versus $2.77 expected, and the company raised its full-year guidance. Despite negative net income margins, operating cash flow remains robust at $738 million in 2025. Analyst sentiment is overwhelmingly positive with 26 buy ratings and a consensus price target of $277.29.

The outlook is supported by improving biotech demand and cost controls, but high valuation multiples and recent insider selling pose risks. Earnings growth and margin expansion are key catalysts, though profitability challenges and macroeconomic sensitivity could pressure the stock. Investors should weigh strong technicals and analyst support against fundamental weaknesses and execution risks.

Nutrien Ltd

Nutrien (NTR) trades at $66.85, up 0.81% today, with a bearish technical signal despite neutral oscillators. Recent Q2 2026 earnings missed EPS estimates but beat on revenue, driven by higher potash prices. The company maintains a stable dividend of $0.55 per share and shows improving net income margins, though cash flow trends have weakened. Analyst consensus is bullish with a $76.17 price target, highlighting structural advantages in nitrogen assets.

The outlook is mixed: strong fundamentals and analyst support suggest upside, but technical weakness and volatile earnings pose risks. Key opportunities include exposure to agricultural cycles and cost advantages; risks involve input cost pressures and execution challenges in a competitive fertilizer market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Nutrien Ltd

Created in 2018 as a result of the merger between PotashCorp and Agrium, Nutrien is the world's largest fertilizer producer by capacity. Nutrien produces the three main crop nutrients--nitrogen, potash, and phosphate--although its main focus is potash, where it is the global leader in installed capacity with roughly 20% share. The company is also the largest agricultural retailer in the United States, selling fertilizers, crop chemicals, seeds, and services directly to farm customers through its brick-and-mortar stores and online platforms.

Read more on NTR